Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

A spokesperson said: “Results from the STEP trials demonstrate that weight regain is likely once medication is stopped.

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Shares of Hims & Hers Health (NYSE:HIMS) reached a session low on Friday after a bipartisan group of U.S. lawmakers urged the ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

The healthcare worker warns that most people will put two thirds of the weight back on within a year of coming off the ...

Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...